As the leading specialist in the non-invasive treatment of small tumors, we are committed to improving patients care by offering high-quality and cost-effective treatments.
Theraclion has developed TH-One, the Scalpel of the Future, in order to offer a 100% scarless solution to treat fine targets such as thyroid nodules, parathyroid glands today. Breast fibroadenomas treatment is currently under clinical investigation.

Thyroid nodules are present in 5% of the population and increase to 50% in the population over 60 years old. Hyperparathyroidism can lead to osteoporosis. Breast fibroadenomas is the most common benign breast tumor. It will concern 10% of women during their life. Those pathologies concern millions of patients who will eventually need surgery or costly medication. 

Theraclion’s technology provides a non-invasive alternative to significantly improve quality of patients life by preventing surgery. Thus, a faster recovery which is key to reduce the cost of healthcare.

Nov. 29, 2011
Successful treatments of two first patients with breast fibroadenoma
> read in English / read in French